Growth Metrics

Heron Therapeutics (HRTX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Heron Therapeutics (HRTX) over the last 12 years, with Q3 2025 value amounting to 45.78%.

  • Heron Therapeutics' EBITDA Margin fell 311500.0% to 45.78% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.78%, marking a year-over-year increase of 114900.0%. This contributed to the annual value of 9.41% for FY2024, which is 775900.0% up from last year.
  • As of Q3 2025, Heron Therapeutics' EBITDA Margin stood at 45.78%, which was down 311500.0% from 6.41% recorded in Q2 2025.
  • Heron Therapeutics' 5-year EBITDA Margin high stood at 8.92% for Q4 2024, and its period low was 272.37% during Q1 2022.
  • In the last 5 years, Heron Therapeutics' EBITDA Margin had a median value of 79.54% in 2023 and averaged 114.02%.
  • In the last 5 years, Heron Therapeutics' EBITDA Margin tumbled by -629000bps in 2021 and then soared by 1985300bps in 2022.
  • Quarter analysis of 5 years shows Heron Therapeutics' EBITDA Margin stood at 264.58% in 2021, then soared by 75bps to 66.04% in 2022, then skyrocketed by 53bps to 31.29% in 2023, then skyrocketed by 128bps to 8.92% in 2024, then crashed by -613bps to 45.78% in 2025.
  • Its EBITDA Margin was 45.78% in Q3 2025, compared to 6.41% in Q2 2025 and 6.74% in Q1 2025.